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doi:10.1016/j.ejvs.2009.07.001Abstract Objectives: The peri-operative use of antiplatelet, anticoagulant and other drugs
for patients undergoing carotid endarterectomy (CEA) is unclear and consensus is lacking. This
study aimed to assess the current peri-operative practice of European vascular surgeons with
respect to antiplatelet and other medications for patients undergoing CEA.
Design: Online questionnaire study.
Methods: Members of the Vascular Society of Great Britain & Ireland and European Society for
Vascular Surgery were invited to complete an online survey in March 2008. Surgeons were
asked about their preferences for the peri-operative administration of antiplatelet, statin
and other medications for patients undergoing carotid endarterectomy.
Results: Partial or complete responses were received from 399/650 (61.4%) surgeons with
a collective annual throughput of >11500 CEA procedures. For symptomatic and asymptomatic
patients, 20/392 (5%) and 47/392 (12%) of surgeons would stop aspirin before surgery and 170/
392 (43%) and 217/392 (55%) of surgeons would stop Clopidogrel prior to CEA. Of surgeons who
would stop Clopidogrel, 84/170 (49%) and 124/217 (57%) would do so >7 days before surgery
for symptomatic and asymptomatic patients respectively. 12/393 (3%) surgeons would prescribe
one 75 mg dose of Clopidogrel on the evening before surgery. Intra-operative Dextran was used
selectively by 40/395 (10%). Only 78/393 (20%) would delay surgery to commence a statin.
Intra-operatively, 348/394 (88%) used intravenous heparin, which was reversed routinely by
47/348 (13%) and selectively by 60/348 (17%).
Conclusions: There appears to be broad consensus between vascular surgeons in the pharmacolog-
icalmanagementofpatientsundergoing carotidendarterectomy,although somevariationsdoexist.
Further clinical studies may help clarify the optimum management strategy in this patient group.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.44 2088467320; fax: þ44
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A Survey of European Vascular Surgeons 403(NASCET),1 the European Carotid Surgery Trial (ECST)2 and
the Asymptomatic Carotid Surgery Trial (ACST)3 have
evaluated the effectiveness of carotid endarterectomy in
patients with significant internal carotid artery stenosis.
These have demonstrated a significant reduction in the risk
of death or disabling strokes for patients randomized to
surgery in comparison to those in the non-surgical arms.
However, consensus is lacking on the peri-operative
prescription of antiplatelet, cholesterol lowering or other
medications for patients requiring carotid endarterectomy
(CEA). A recent meta-analysis reported that aspirin was
protective in most patients at increased risk of occlusive
vascular events.4 Furthermore, large randomized clinical
studies have demonstrated reductions in stroke and death
rates in patients treated with aspirin after stroke.5
These findings suggest that a period of pre-operative
administration followed by post-operative administration
of aspirin may have a protective effect in patients
undergoing CEA.
In order to maintain low complication rates following
CEA, multiple components of the pre, intra and post-
operative care must be carefully managed. Tsurgical tech-
nique and appropriate use hese factors include patient
selection, assessment of cardiac risk factors, precise blood
pressure control, meticulous of antiplatelet, anti-
coagulation and other medications. The aim of this study
was to evaluate the use of peri-operative antiplatelet,
anticoagulant and other medications amongst European
Vascular Surgeons.
Materials and Methods
An email invitation to complete an online 16-part ques-
tionnaire was sent to all listed members of the European
Society of Vascular Surgery (ESVS) and the Vascular Society
of Great Britain and Ireland (VSGBI). The societies were not
involved in the design of the study. Questions relating to
the pre, peri and post-operative pharmacological manage-
ment of patients undergoing CEA were devised by the study
authors (Appendix 1). Questions related to pre-operative
antiplatelet, anticoagulant and statin use; intra-operative
heparin, dextran, protamine and dexamethasone use and
post-operative antiplatelet use. The initial invitation email
was sent in March 2008 and a reminder email was sent in
June 2008. The questionnaire responses were anonymized
and only one response per email address was allowed by the
online academic survey software (Bristol Online Surveys).
All complete and partially completed responses were
included in the analysis and the number of completed
responses received for each question is presented as the
denominator. Statistical analysis was performed using the
Chi Square test (SPSS v16.0, Chic, IL, USA).Table 1 Numbers of respondents who would stop antiplatelet a
Patient category Aspirin Clopidogr
Symptomatic 20/392(5.1%) 170/392(
Asymptomatic 47/392(11.9%) 217/392(
pZ 0.001* pZ 0.001
* Chi-square test.Results
Partial or completed questionnaires were received from 399
of the 650 (61.4%) Vascular Surgeons invited to participate.
Published email addresses were inaccurate for 98/650
(15.1%) and 153/650 (23.5%) did not respond. A total of 284
responseswere received after the initial invitation email and
a further 115 responses were received after the reminder
email. The combined throughput of those who completed
the survey was >11,500 CEA procedures per annum. Of the
361 respondents that answered the specific question, 239
(66.2%) performed >20 CEA procedures per annum.
Procedures were routinely performed using general anaes-
thesia by 178/362 (49.1%) whereas 151/362 (41.7 %) used
local anaesthesia and 33/362 (9.1%) used both techniques.
Pre-operative management
The vast majority of vascular surgeons surveyed would not
stop aspirin prior to carotid endarterectomy for symptom-
atic or asymptomatic patients (372/392 [94.8%] and 345/
392 [88.0%] respectively) (Table 1). Of the 47 respondents
that would discontinue aspirin (including 20 who would do
so for patients with symptomatic and asymptomatic carotid
stenosis), 33/47 (70.2%) would do so 1e7 days before
surgery and 14/47 (29.8%) would stop aspirin for at least 7
days. When asked about pre-operative Clopidogrel use,
170/392 (43.3%) and 217/392 (55.3%) of surgeons would
stop Clopidogrel before surgery for symptomatic and
asymptomatic patients respectively. Of surgeons who would
stop Clopidogrel, 84/170 (49.4%) and 124/217 (57.1%) would
do so >7 days before surgery for symptomatic and asymp-
tomatic patients respectively. For both aspirin and Clopi-
dogrel, surgeons were more likely to stop antiplatelet
medications prior to surgery for asymptomatic rather that
symptomatic carotid stenosis (pZ 0.001, pZ 0.001
respectively, Chi Squared test) (Table 1).
A high proportion of respondents stated that they would
continue Dipyridamole prior to surgery for symptomatic or
asymptomatic disease; 247/250 (98.8%) and, 211/250
(84.4%) respectively. A total of 285/392 (72.7%) and 389/
392 (99.2%) of respondents would stop Warfarin prior to CEA
(Table 1). Interestingly, 12/393 (3.0%) of surgeons would
prescribe a pre-operative 75 mg dose of Clopidogrel, the
day before surgery. CEA would be delayed by surgeons
to give statin medication by 18/393 (4.9%) for symptomatic
patients and 60/393 (15.2%) for asymptomatic patients.
Intra-operative management
Only 13/394 (3.2%) surgeons would give intra-operative
pooled platelets if the patient was on dual antiplateletnd anticoagulant medications prior to CEA
el Dipyridamole Warfarin
43.3%) 83/394(21.0%) 285/392(72.7%)
55.3%) 93/394(23.6%) 389/392(99.2%)
* pZ 0.441* pZ 0.001*
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majority of surgeons would routinely give heparin prior to
arterial clamping (348/394 [88.3%]), but only 47/348
(13.5%) would routinely reverse the heparin and 60/348
(17.2%) would reverse it selectively. Regarding blood pres-
sure management during surgery, 245/394 (62.1%) would
aim to maintain normotension during CEA, although 97/394
(24.6%) would aim to keep patients hypertensive. Dextran
was routinely prescribed by 40/397 (10.0%) of respondents
and selectively (based on transcranial Doppler readings) by
a further 27/397 (6.8%). Dexamethasone was used routinely
or selectively by a minority of respondents; 14/363 (3.8 %)
and 35/363 (9.6%) respectively.
Post-operative management
Among the surgeons who would discontinue antiplatelet
drugs, 18/20 (90.0%) would restart aspirin and 131/189
(69.3%) would restart Clopidogrel on first day post-opera-
tively (Table 2).
Discussion
This survey demonstrated that the majority of European
Vascular Surgeons who responded would continue aspirin,
but most would stop other antiplatelet and anticoagulant
medications prior to carotid endarterectomy. Moreover,
most respondents would use heparin intra-operatively, aim
tomaintain normal blood pressure during surgery and restart
antiplatelet medications on the first post-operative day.
Although a broad consensus was seen, it is worth noting that
some variation in the clinical practice of European Vascular
Surgeons was demonstrated in this study, highlighting the
scarcity of level 1 evidence or clinical guidelines in this area.
The decision to continue to stop antiplatelet and anti-
coagulant drugs requires the clinician to evaluate the risks
and benefits for each individual patient and balance the risks
of bleeding and thrombosis. In a study that investigated the
use of 75 mg of Clopidogrel in addition to 150 mg of aspirin,
a significant reduction in peri-operative emboli was seen
without any increase in bleeding complications or blood
transfusion.6 A recent systematic review found that the risk
of peri-operative stroke among those receiving antiplatelet
agents was significantly reduced in comparison with the risk
for those not receiving antiplatelet therapy, but that the
risks of peri-operative death in the two groups were not
significantly different.7 Another study suggested that
a single 75-mg dose of Clopidogrel, taken the evening before
carotid endarterectomy, may reduce post-operative embo-
lisation, a marker of thrombo-embolic stroke.8 Moreover,
a recent meta-analysis suggested that the use of Dipyr-
idamole in combination with aspirin may be the best choice
for secondary prevention of vascular events after stroke orTable 2 Time to restarting antiplatelet and anticoagulant med
Patient category Aspirin Clopidogr
Day 1 18/20(90.0%) 131/189(
Day 2e6 1/20(5.0%) 52/189(2
Day 7 1/20(5.0%) 6/189(3.1TIA.9 Despite these studies, 5e12% of surveyed surgeons
would stop aspirin andmore than half would stop Clopidogrel
pre-operatively. Clearly, further clinical studies demon-
strating clear benefits are needed before dual antiplatelet
therapy is widely adopted by surgeons performing CEA.
Interestingly, a small proportion of surgeons would delay
carotid endarterectomy for a week or more in order to give
statins. The use of statins has been suggested as a potential
method of plaque stabilization prior to CEA, a hypothesis
supported by histological studies.10 Clinical studies have
also shown lower rates of adverse events in patients taking
statins prior to CEA.8 Interestingly, large studies have sug-
gested that this benefit is greatest in symptomatic rather
than asymptomatic patients.11,12 In a retrospective study,
McGirt et al. suggested that peri-operative statin use (at
least for one week before surgery and one month after)
may reduce the incidence of cerebrovascular events and
mortality among patients undergoing CEA.13 A further study
demonstrated that 4 weeks of treatment with atorvastatin
resulted in significant local and systemic reductions in
inflammatory mediators in patients undergoing carotid
endarterectomy. These findings suggest that statins may
reduce atherosclerotic plaque inflammation and potentially
delay or prevent plaque rupture.14 These observations are
intriguing, but more definitive studies are needed before
broad recommendations can be agreed. A strategy of
delaying CEA for the administration of statins may seem
logical in asymptomatic patients, but may be detrimental in
symptomatic patients. The increasingly widespread use of
statins in high-risk populations is likely to mean that the
vast majority of patients requiring CEA will already be on
cholesterol lowering medication.
The maintenance of hypertension (around 20% above
pre-operative systolic pressure) during CEA may be justified
by fears of ‘watershed’ stroke during carotid cross-
clamping15 and evidence from patients undergoing awake
CEA where neurological deficits may be reversed by
elevation of arterial pressure.16 However, most clinicians
would agree that absolute values or targets should be
viewed as guidelines only and adapted to individual
patients,17 particularly as augmentation of arterial pressure
may be associated with increased risks, including a higher
incidence of myocardial infarction18 and intracerebral
haemorrhage.19 Dextran is thought to prevent platelet
adherence to the endarterectomy site, although its role in
CEA remains unclear. There is evidence to suggest that
dextran 40 may reduce the incidence of post-operative
emboli and stroke (assessed using transcranial Doppler).20
Corticosteroids (dexamethasone 24e40 mg/day in divided
doses) may reduce vasogenic cerebral oedema, but their
routine use in treatment of ischaemic strokes is doubtful.21
Studies evaluating peri-operative corticosteroids in
patients treated with CEA are scarce, although a recentications
el Dipyridamole Warfarin
69.3%) 78/110(70.9%) 84/184(45.6%)
7.5%) 30/110(27.2%) 88/184(47.8%)
%) 2/110(1.8%) 12/184(6.4%)
A Survey of European Vascular Surgeons 405randomized trial did suggest that dexamethasone may be
effective in reducing the incidence of temporary cranial
nerve injuries during CEA.22
We recognize that survey studies are often limited by
poor response rates. The response rate in this study was
only 61%, although this compares favourably with other
similar studies.23 Moreover, it is likely that a large number
of surgeons (not members of ESVS or VSGBI) were not
included and heterogeneity in clinical practice across
Europe may limit the generalisability of this study. Another
limitation of this study was the lack of questions on the
management of patients taking dual antiplateletAppendix 1
Survey questionnaire.
No. Question
1e4 Please indicate if you would routinely
stop the following medications prior to CEA:
 Aspirin
 Clopidogrel
 Dipyridamole
 Warfarin
5 Do you use an additional antiplatelet
medication pre-operatively?
6 If a patient is not taking a statin would you
delay endarterectomy in order to start one?
7 If you do not routinely stop antiplatelet medication,
would you routinely give patients additional platelets?
8 Intra operatively do you routinely give
heparin before clamping the arteries?
9 If you do give heparin before clamping
the arteries, do you reverse it?
10 Intra operatively, how best describes the
patients’ systolic blood pressure before
clamping the arteries?medications, which is an increasingly common clinical
scenario. In conclusion, there appears to be broad
consensus between vascular surgeons in the use of anti-
platelet and statins for patients undergoing carotid endar-
terectomy, although some variations do exist. Only by
establishing evidence-based guidelines can we achieve
greater consistency of treatment for this patient group.Conflict of Interest/Funding
None.Choice of responses
a. Do not stop prior to surgery
b. Stop> 7 days pre-op
c. Stop 2e7 days pre-op
d. Stop 48 h pre-op
e. Stop <48 h pre-op
f. Other (specify)
g. No Answer
a. no
b. Yes, if yes please specify below
c. Clopidogrel one dose pre-operatively only
d. Clopidogrel 48 h pre-operatively
e. Clopidogrel 7 days pre-operatively
f. Other
g. No Answer
a. No
b. Yes 7 days
c. Yes 1e6 weeks
d. Yes More than 6 weeks
e. Other
f. No Answer
a. No
b. Yes if the patient is on aspirin
c. Yes but only if the patient is on Clopidogrel
d. Yes but only if the patient is taking aspirin and Clopidogrel
e. Yes if the patient is taking aspirin and Dipyridamole
f. No Answer
a. Yes
b. No
c. Selectively
d. Other
e. No Answer
a. Yes
b. No
c. Selectively
d. Other
e. No Answer
a. Normotensive
b. Hypertensive
c. Hypotensive
d. Other
e. No Answer
(continued on next page)
Appendix (continued )
No. Question Choice of responses
11 Peri-operatively, do you give dextran? a. Yes
b. No
c. Selectively based on TCD
d. Selectively based on clinical assessment
e. No Answer
12 Peri-operatively do you give dexamethasone? a. Yes
b. No
c. Selectively based on TCD
d. Selectively based on clinical assessment
e. No Answer
13 If you usually stop antiplatelet
medication prior to surgery, when do you restart it?
a. Aspirin Day1 Day 2e6 After day 7
b. Clopidogrel
c. Dipyridamole
d. Warfarin
e. No Answer
14 On average how many carotid endarterectomy
procedures do you perform in one year?
a. Less than 10
b. 11e20
c. 21e30
d. 31e50
e. Over 50
f. No Answer
15 What type of anaesthesia do you use for the
majority of your carotid endarterectomy procedures?
a. General anaesthesia
b. Local anaesthesia
c. Equal numbers of each
d. No Answer
16 Which antiplatelet medications do you routinely
prescribe for patients requiring carotid endarterectomy?
(please select all that)
a. Aspirin
b. Clopidogrel
c. Dipyridamole
d. other
f. No Answer
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